NEW YORK – Acepodia on Thursday closed a $109 million Series C funding round led by Digital Mobile Venture.
The funding will be used to advance Acepodia's antibody-cell conjugation platform, which the firm is using to develop a pipeline of off-the-shelf antibody cell effector, or ACE, therapies, including drugs targeting HER2, CD20, and PD-L1. Acepodia's lead candidate ACE1702 is a natural killer (NK)-cell therapy, which the firm is studying in HER2-expressing solid tumors in a Phase I trial. Acepodia's other candidates are in the preclinical phase.
Acepodia, located in San Mateo, California, and Taiwan, has raised a total of $166 million since its founding in 2017, including $47 million in a Series B funding round in March. Investors have included Ridgeback Capital Investments, 8VC, DEFTA Partners, CDIB Capital Healthcare, Maxpro, E-Sun Venture, BioEngine Venture, Samuel Chen, Yahoo founder Jerry Yang, and Foxconn founder Terry Gou. With the latest financing, Samuel Chen, director at Digital Mobile Venture, will join the Acepodia board of directors.